The Infectious Diseases Society of America (IDSA) is encouraged by the recent development of direct-acting antivirals for the treatment of hepatitis C virus (HCV). With an estimated 3 to 4 million Americans infected with HCV, the potential for cure offered by these new drugs for a majority of patients with HCV represents a significant medical advancement.
There are many factors that impact an individual patient’s access to care – availability of and access to appropriate health care practitioners, insurance benefit design (including drug coverage and cost-sharing), and drug affordability. IDSA recognizes the substantial investment in research and development required to bring new, effective drugs to patients. We are, however, concerned that pricing of new drugs may put such therapy out of reach for many patients who are most in need of these life-saving drugs. IDSA is hopeful that the various stakeholders can work together to maximize patient access to optimal care.
1300 Wilson Boulevard Suite 300 Arlington, VA 22209 | Phone: (703) 299-0200 | Fax: (703) 299-0204
| HIVMA | Contact Us
© Copyright IDSA 2017 Infectious Diseases Society of America